Exact Sciences Corporation (EXAS) - News Archive

MADISON, Wis. Exact Sciences Corp. (NASDAQ: EXAS), a recognized leader in the field of cancer screening and diagnostic tests, has announced unprecedented results from its landmark ALTUS study (NCT: 05064553). These pivo...

Exact Sciences Launches Groundbreaking Cancerguard Test: Pioneering Multi-Cancer Early Detection Amidst Revenue GrowthIn a significant advancement within the cancer diagnostics landscape, Exact Sciences Corp. (Nasdaq: E...

In a significant advancement for colorectal cancer (CRC) patients, Exact Sciences Corp., a leading player in cancer diagnostics, recently announced that its Oncodetect molecular residual disease (MRD) test will now be c...

Exact Sciences Corp. (Nasdaq: EXAS), a pioneering company in the field of cancer diagnostics, has unveiled compelling clinical data, reaffirming the efficacy of its Oncodetect™ MRD test in detecting molecular residual d...

A New Era in Colorectal Cancer Screening: The FDA s Approval of Exact Sciences Cologuard Plus In a landmark decision, the U.S. Food and Drug Administration (FDA) has bestowed its approval upon Exact Sciences Corp. s new...

MADISON, Wis. Exact Sciences Corp. (NASDAQ: EXAS), an industry leader in cancer screening and diagnostics, has unveiled groundbreaking performance data for its innovative blood-based colorectal cancer screening test. Th...

MADISON, Wis. Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, continues to push the boundaries in cancer early detection and diagnostics, as evidenced by two significant...

In a landscape where timely cancer detection can mean the difference between life and death, Exact Sciences Corp. has heralded a transformative tool in the diagnostic realm the Cologuard test. The latest modeling data p...

MADISON, Wisconsin - Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer early detection and diagnostic tests, will present 10 abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting,...

MADISON, Wisconsin Exact Sciences Corp. (Nasdaq: EXAS), a pioneering provider of cancer screening and diagnostic tests, continues to solidify its leadership in the field of oncology. The company is set to showcase 10 ab...

Exact Sciences Corp. (Nasdaq: EXAS), a front-runner in the field of cancer diagnostics and screening, is set to assert its dominance in early cancer detection with a robust presentation at the upcoming annual meeting of...

Exact Sciences, a leading provider of cancer screening and diagnostic tests, recently showcased its continued leadership and groundbreaking advancements in early cancer diagnosis at this year s American Society of Clini...

In a significant development for the healthcare and biotechnology sectors, leading cancer screening and diagnostic test provider, Exact Sciences Corp., has been granted permission to proceed with a patent infringement l...